GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Book Value per Share

ATNM (Actinium Pharmaceuticals) Book Value per Share : $1.23 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Book Value per Share?

Actinium Pharmaceuticals's book value per share for the quarter that ended in Sep. 2024 was $1.23.

During the past 12 months, Actinium Pharmaceuticals's average Book Value Per Share Growth Rate was -23.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -27.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Actinium Pharmaceuticals was 110.40% per year. The lowest was -95.50% per year. And the median was -7.60% per year.

Actinium Pharmaceuticals's current price is $1.40. Its book value per share for the quarter that ended in Sep. 2024 was $1.23. Hence, today's PB Ratio of Actinium Pharmaceuticals is 1.14.

During the past 13 years, the highest P/B Ratio of Actinium Pharmaceuticals was 6.99. The lowest was 0.98. And the median was 2.32.


Actinium Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Actinium Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Book Value per Share Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 3.50 3.32 2.59 1.32

Actinium Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.32 1.49 1.44 1.23

Competitive Comparison of Actinium Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Actinium Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's PB Ratio falls into.



Actinium Pharmaceuticals Book Value per Share Calculation

Actinium Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(36.38-0.00)/27.63
=1.32

Actinium Pharmaceuticals's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(38.21-0.00)/31.20
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Actinium Pharmaceuticals  (AMEX:ATNM) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Actinium Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Executives
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin officer: VP, Finance and Corporate Dev. 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig officer: Chief Scientific Officer 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell director 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty director 643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur officer: Chief Commercial Officer 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray officer: Executive Vice President 14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center 10 percent owner 1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa director 138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave director, officer: President and CEO 4 WATER STREET, EDISON NJ 08820
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc 10 percent owner C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd. 10 percent owner C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000

Actinium Pharmaceuticals Headlines

From GuruFocus